- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Unresectable Stage III non-small cell lung cancer
- Meeting Date: March 2022
- Public Summary Document (PSD) March 2022 PBAC Meeting - (PDF 425KB)
- Public Summary Document (PSD) March 2022 PBAC Meeting - (Word 72KB)
Durvalumab – March 2022
Durvalumab: Solution concentrate for I.V. infusion 500 mg in 10 mL; Imfinzi®
Last updated
1 July 2022